If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...

Copyright: © 2019 Elsevier Ltd. All rights reserved.

Brepocitinib is a first-in-class, oral, selective TYK2–JAK1 inhibitor that blocks cytokine signaling, which has been implicated in dermatomyositis. In this phase 3, double-blind, randomized, ...

Level 1 of 3 · the shared message. This section is identical in every repository of this system. Level 3 of 3 · what this one is. HUF (Higgins Unity Framework) is the experimental origin, governance ...

Introduction Epidermolysis bullosa (EB) is a group of rare genetic skin disorders characterised by skin and mucosal fragility, leading to painful blisters and erosions. Among its subtypes, the severe ...

After the FDA revoked Sarepta Therapeutics’ platform designation in July, Krystal Biotech is “poised to be the first major beneficiary” of this program, according to analysts at William Blair. The FDA ...

The herpes simplex virus type 1 (HSV-1), which affects almost two-thirds of the world's population and is generally associated with oral herpes, may cause painful cold sores or fever blisters around ...

Abstract: The paper presents a peak-search method for active continuous wave (CW) load-pull measurements for implementation in an autonomous characterization system aimed at optimizing mmWave RF power ...

Despite the widespread success of neural networks, their susceptibility to adversarial examples remains a significant challenge. Adversarial training (AT) has emerged as an effective approach to ...

The primary objective of ARCADIA 1 and ARCADIA 2, which were two large-scale phase 3 studies, was to assess the efficacy and safety of nemolizumab, in addition to background topical therapy, after a ...